We report two cases of chronic GVHD presenting with polymyositis manifestations 13 and 19 months after allogeneic hematopoietic stem cell transplant, successfully treated with corticosteroids and ...

New research from Tokyo, Japan could help clarify the role of proinflammatory mediators in the pathogenesis of chronic inflammatory myopathies, such as polymyositis and dermatomyositis.

Belonging to the same group of autoimmune diseases, both dermatomyositis and polymyositis cause muscle inflammation and weakness. But dermatomyositis also affects your skin and is more likely to ...

08, 2021 (GLOBE NEWSWIRE) -- DelveInsight’s ‘Polymyositis Pipeline Insight 2021’ report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases ...

PF1801 is a novel long-acting glucagon-like peptide-1 receptor agonist. The Food and Drug Administration (FDA) has granted Orphan Drug designation to PF1801 for the treatment of polymyositis.